Astragaloside iv inhibits the up-regulation of Wnt/β-catenin signaling in rats with unilateral ureteral obstruction

Cellular Physiology and Biochemistry

Volumn 33, Issue 5, 2014, Pages 1316-1328

  Wang, Li ^b   Chi, Yang Feng ^a   Yuan, Ze Ting ^a   Zhou, Wen Chao ^a   Yin, Pei Hao ^a   Zhang, Xue Mei ^c   Peng, Wen ^a,b  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^b Laboratory of Renal Disease   (China)

^c FUDAN UNIVERSITY   (China)

Author keywords

Astragaloside IV; Renal interstitial fibrosis; UUO model; Wnt catenin signaling pathway

Indexed keywords

ASTRAGALOSIDE IV; BETA CATENIN; FRIZZLED PROTEIN; GELATINASE A; JAGGED1; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 5; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN 6; LYMPHOID ENHANCER FACTOR 1; MATRILYSIN; TRANSCRIPTION FACTOR 7; TRANSCRIPTION FACTOR SNAIL; UVOMORULIN; WNT PROTEIN; WNT3 PROTEIN; WNT4 PROTEIN; APC PROTEIN; TRANSCRIPTION FACTOR TWIST; ASTRAGALOSIDE A; SAPONIN; TRITERPENE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; IMMUNOHISTOCHEMISTRY; KIDNEY FIBROSIS; MALE; NONHUMAN; PRIORITY JOURNAL; RAT; REAL TIME POLYMERASE CHAIN REACTION; UPREGULATION; URETER LIGATION; URETER OBSTRUCTION; WNT SIGNALING PATHWAY; FIBROSING ALVEOLITIS; FLUORESCENCE; PROTEIN EXPRESSION; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; WESTERN BLOTTING; ANIMAL; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECTS; METABOLISM; ORAL DRUG ADMINISTRATION; PATHOLOGY; SPRAGUE DAWLEY RAT; URETERAL OBSTRUCTION;

GASTROPODA; RATTUS;

ADMINISTRATION, ORAL; ANIMALS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; RATS; RATS, SPRAGUE-DAWLEY; SAPONINS; TRITERPENES; UP-REGULATION; URETERAL OBSTRUCTION; WNT SIGNALING PATHWAY;

EID: 84899614526     PISSN: 10158987     EISSN: 14219778     Source Type: Journal    
DOI: 10.1159/000358699     Document Type: Article

References (44)

1. Zeisberg M, Neilson EG: Mechanisms of tubulointerstitial fibrosis. J Am Soc Nephrol 2010;21:1819-1834.
2. Ning XH, Ge XF, Cui Y, An HX: Ulinastatin inhibits unilateral ureteral obstruction-induced renal interstitial fibrosis in rats via transforming growth factor beta (TGF-beta)/Smad signalling pathways. Int Immunopharmacol 2013 ;15:406-413.
3. Ho C, Lee PH, Hsu YC, Wang FS, Huang YT, Lin CL: Sustained Wnt/beta-catenin signaling rescues high glucose induction of transforming growth factor-beta1-mediated renal fibrosis. Am J Me d Sci 2012;344:374-382.
4. Qin J, Xie YY, Huang L, Yuan QJ, Mei WJ, Yuan XN, Hu GY, Cheng GJ, Tao LJ, Peng ZZ: Fluorofenidone inhibits nicotinamide adeninedinucleotide phosphate oxidase via PI3K/Akt pathway in the pathogenesis of renal interstitial fibrosis. Nephrology 2013;18:690-699.
5. MacDonald BT, Tamai K, He X: Wnt/beta-catenin signaling: Components, mechanisms, and diseases. Dev Cell 2009:17:9-26.
6. Surendran K, Schiavi S, Hruska KA: Wnt-dependent beta-catenin signaling is activated after unilateral ureteral obstruction, and recombinant secreted frizzled-related protein 4 alters the prog ression of renal fibrosis. J Am Soc Nephrol 2005:16:2373-2384. (Pubitemid 41725055)
7. Dai C, Stolz DB, Kiss LP, Monga SP, Holzman LB, Liu Y: Wnt/beta-catenin signaling promotes podocyte dysfunction and albuminuria. J Am Soc Nephrol 2009:20:1997-2008.
8. Naves MA, Requiao-Moura LR, Soares MF, Silva-Junior JA: Mastroianni-Kirsztajn G, Teixeira VP, Podocyte Wnt/ss-catenin pathway is activated by integrin-linked kinase in clinical and experimental focal segmental glomerulosclerosis. J Nephrol 2012;3:401-409.
9. He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF, Liu Y: Matrix metalloproteinase-7 as a surrogate marker pr edicts renal Wnt/beta-catenin activity in CKD. J Am Soc Nephrol 2012;23:294-304.
10. Guo Y, Xiao L, Sun L, Liu F: Wnt/beta-catenin signaling: A promising new target for fibrosis diseases. Physiol Res 2012;61:337-346.
11. He W, Dai C, Li Y, Zeng G, Monga SP, Liu Y: Wnt/beta-catenin signaling promotes renal interstitial fibrosis. J Am Soc Nephrol 2009;20:765-776.
12. Liu Y, New insights into epithelial-mesenchymal transition in kidney fibrosis, J Am Soc Nephrol,2010, 21, 212-222.
13. He J, Xu Y, Koya D, Kanasaki K: Role of the endothelial-to-mesenchymal transition in renal fibrosis of chronic kidney disease. Clin Exp Nephrol 2013;17:488-497.
14. Li R, Wang Y, Liu Y, Chen Q, Fu W, Wang H, Cai H, Peng W, Zhang X: Curcumin inhibits transforming growth factor-beta1-induced EMT via PPARgamma pathway, not Smad pathway in renal tubular epithelial cells. PLoS One, 2013;8:e58848.
15. Yu QT, Qi LW, Li P, Yi L, Zhao J, Bi Z: Determination of seventeen main flavonoids and saponins in the medicinal plant Huang-qi (Radix astragali) by HPLC-DAD-ELSD. J Sep Sci 2007;30:1292-1299. (Pubitemid 46979326)
16. Qiu LH, Xie XJ, Zhang BQ: Astragaloside IV improves homocysteine-induced acute phase endothelial dysfunction via antioxidation. Biol Pharm Bull 2010:33:641-646.
17. Zhao J, Yang P, Li F, T ao L, Ding H, Rui Y, Cao Z, Zhang W: Therapeutic effects of Astragaloside IV on myocardial injuries: Multi-target identification and network analysis. PLoS One 2012;7:e44938.
18. Gui D, Huang J, Liu W, Guo Y, Xiao W, Wang N: Astragaloside IV prevents acute kidney injury in two rodent models by inhibiting oxidative stress and apoptosis pathways. Apoptosis 2013;18:409-22.
19. Gui D, Guo Y, Wang F, Liu W, Chen J, Chen Y, Huang J, Wang N: Astragaloside IV, a novel antioxidant, prevents glucose-induced podocyte apoptosis in vitro and in vivo. PLoS One 2013;7:e39824.
20. Gui D, Huan g J, Guo Y, Chen J, Chen Y, Xiao W, Liu X, Wang N: Astragaloside IV ameliorates renal injury in streptozotocin-induced diabetic rats through inhibiting NF-kappaB-mediated inflammatory genes expresonCy1-okine9013-61-970-977
21. Qi W, Niu J, Qin Q, Qiao Z, Gu Y: Astragaloside IV attenuates glycated albumin-induced epithelial-to-mesenchymal transition by inhibiting oxidative stress in renal proximal tubular cells. Cell Stress Chaperones 2014;19:105-114.
22. Chevalier RL, Forbes MS, Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009;75:1145-1152.
23. Komiya Y, Habas R: Wnt signal transduction pathways. Organogenesis 2008;4:68-75. (Pubitemid 351881302)
24. Filipovich A, Gehrke I, Poll-Wolbeck SJ, Kreuzer KA: Physiological inhibitors of Wnt signaling. Eur J Haematol 2011;86:453-465.
25. Michael DG, Nusse R: Wnt signaling: Multiple pathways, multiple receptors, and multiple transcription factors. J Biol Chem 2006;11:22429-22433.
26. Gordon MD, Nusse R: Wnt4/beta-catenin signaling in medullary kidney myofibroblasts. J Am Soc Nephrol 2013;24:1399-1412.
27. Surendran K, McCaul SP, Simon TC: A role for Wnt-4 in renal fibrosis. Am J Physiol Renal Physiol 2002;282:F431-F441.
28. He W, Tan RJ, Li Y, Wang D, Nie J, Hou FF, Liu Y: Matrix metalloproteinase-7 as a surrogate marker predicts renal Wnt/beta-catenin activity in CKD. J Am S oc Nephrol 2012;23:294-304.
29. Surendran K, Simon TC, Liapis H, McGuire JK: Matrilysin (MMP-7) expression in renal tubular damage: Association with Wnt4. Kidney Int 2004;65:2212-2222. (Pubitemid 38670007)
30. Kalluri R, Neilson EG: Epithelial-mesenchymal transition and its implications for fibrosis. J Clin Invest 2003;112:1776-1784. (Pubitemid 38063698)
31. Orsulic S, Huber O, Aberle H, Arnold S, Kemler R: E-cadherin binding prevents beta-catenin nuclear localization and beta-catenin/LEF-1-mediated transactivation. J Cell Sci 1999;112:1237-1245. (Pubitemid 29218912)
32. Zheng G, Lyons JG, Tan TK, Wang Y, Hsu TT, Min D, Succar L, Rangan GK, Hu M, Henderson BR, Alexander SI, Harris DC: Disruption of E-cadherin by matrix metalloproteinase directly mediates epithelial-mesen chymal transition downstream of transforming growth factor-beta1 in renal tubular epithelial cells. Am J Pathol 2009;175:580-591.
33. Du X Shimizu A Masuda Y Kuwahara N Arai T Kataoka M Uchiyama M Kaneko T Akimoto T Iino Y Fukuda Y Involvement of matrix metalloproteinase-2 in the development of renal interstitial fibrosis in mouse obstructive nephropathy Lab Invest, 2012, 92,1149-1160.
34. Tan TK, Zheng G, Hsu TT, Wang Y, Lee VW, Tian X, Wang Y, Cao Q, Wang Y, Harris DC: Macrophage matrix metalloproteinase-9 mediates epithelial-mesenchymal transition in vitro in murine renal tubular cells. Am J Pathol 2010;176:1256-1270.
35. Zhao H, Dong Y, Tian X, Tan TK, Liu Z, Zhao Y, Zhang Y, Harris DCh, Zheng G: Matrix metalloproteinases contribute to kidney fibrosis in chronic kidney diseas es. World J Nephrol 2013;2:84-89.
36. Tan X, Li Y, Liu Y: Paricalcitol attenuates renal interstitial fibrosis in obstructive nephropathy. J Am Soc Nephrol 2006;17:3382-3393. (Pubitemid 44865281)
37. Boutet A, De Frutos CA, Maxwell PH, Mayol MJ, Romero J, Nieto MA: Snail activation disrupts tissue homeostasis and induces fibrosis in the adult kidney. EMBO J 2006;25:5603-5613. (Pubitemid 44847200)
38. Yang MH, Wu KJ: TWIST activation by hypoxia inducible factor-1 (HIF-1): Implications in metastasis and development. Cell Cycle 2008;7:2090-2096.
39. Kawano Y, Kypta R: Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-2634. (Pubitemid 36857216)
40. He W, Kang YS, Dai C, Liu Y: Blockade of Wnt/beta-catenin signaling by paricalcitol ameliorates proteinuria and kidney injury. J Am Soc Nephrol 2011;22:90-103.
41. Kim K, Lu Z, Hay ED: Direct evidence for a role of beta-catenin/LEF-1 signaling pathway in induction of EMT. Cell Biol Int 2002;26:463-476. (Pubitemid 34762099)
42. Henderson BR: Nuclear-cytoplasmic shuttling of APC regulates beta-catenin subcellular localization and turnover. Nat Cell Biol 2000;2:653-660.
43. Meng LQ, Tang JW, Wang Y, Zhao JR, Shang MY, Zhang M, Liu SY, Qu L, Cai SQ, Li XM: Astragaloside IV synergizes with ferulic acid to inhibit renal tubulointerstitial fibrosis in rats with obstructive nephropathy. Br J Pharmacol 2011;162:1805-1818.
44. Chevalier RL, Forbes MS, Thornhill BA: Ureteral obstruction as a model of renal interstitial fibrosis and obstructive nephropathy. Kidney Int 2009;75:1145-1152.